Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Fibromun (Primary) ; Doxorubicin
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Philogen
- 27 Aug 2019 Planned End Date changed from 9 Jul 2019 to 1 Oct 2019.
- 19 Mar 2019 Planned End Date changed from 1 Jun 2018 to 9 Jul 2019.
- 19 Mar 2019 Status changed from recruiting to active, no longer recruiting.